Innovative Lung Health Solutions
Transforming lung treatment through AI and data-driven insights.
About TRISYNTEC
Our Biotech Global JV Focus
We focus on de novo biotechnology solutions and design products for patient care applications targeting pulmonary disease crises. Our primary markets include India, Africa, the Middle East, the EU, and the US.
Optimizing the Patient Experience and Outcome
The Econophy Group is rebranding as TRISYNTEC, a comprehensive source provider of three digital health biotech assets that create collaborative and comprehensive treatment solutions. The collective process results in a higher efficacy patient care treatment, at a lower cost basis, and a shortened treatment timeline, resulting in an extended life expectancy.
Developed in early 2024, our biotech global JV consists of three de novo assets that target TB & COPD. Tuberculosis is the leading cause of death from an infectious disease worldwide. Global COPD prevalence is projected to approach 600 million cases worldwide by 2050.
Since presenting as a showcase company at the Brussels Pharma Partnering Summit, our Phase III first-in-class NMMI diagnostic analysis integrates a wearable, multi-country patented therapeutic device transmitting real-world data (RWD) and real-world evidence (RWE) to a predictive, AI epidemiology platform focused on pulmonary diseases.
The device's therapeutic applications include COPD, TB, sleep apnea, and in the future, PTSD.
As a specialized pulmonary disease AI resource, it will focus on and feature an automated diagnosis tool for MDs to simplify disease diagnosis and increase its accuracy. It will also provide governments, insurance companies, healthcare providers, public and private research facilities, and pharma companies with data analytics to mitigate diagnostic errors, disease spread, and unnecessary treatment costs, and help to solve other large-scale health industry problems.
What is the extent and impact of diagnostic error or misdiagnosis?
- Most Americans will experience at least one misdiagnosis in their lifetime.
- $750 billion, or 30% of annual health care spending, is wasted in unnecessary services and other inefficiencies, including diagnostic error, contributing to a loss of productivity in the US economy.
- Between 40,000 and 80,000 patients die each year in the US due to diagnostic errors.
- International markets require crisis-oriented POC (point of care) treatments due to a lack of an innovative solution provider with efficacy, capability, impact, and scalability that will address unmet needs and global costs versus benefit issues.
- Current diagnostic technologies have limited capabilities and efficacy.
- Vascular events, infections, and cancers account for 75% of the serious harm.
- When undiagnosed, chronic obstructive pulmonary disease (COPD) can reduce life expectancy by 0.3 to 6 years. People with severe COPD can lose 8 to 9 years of life expectancy on average.
International markets require crisis-oriented POC (point of care) treatments due to a lack of an innovative solution provider with efficacy, capability, impact, and scalability that will address unmet needs and global costs versus benefit issues.
The NMMI market is driven by the growing adoption of SPECT/CT hybrid imaging systems and the increased use of nuclear medicine and molecular technology for detecting diseases at an early stage.
Our JV Partner Relationships
They consist of PhDs, MDs, and senior executives of multi-country clinical research organizations (CROs), business development, and commercialization firms, who have been industry veterans for 20+ years. Our PhD data specialist partner is formerly a senior project manager at the National Institutes of Health.
Future Capital Market Offering Events
Our structure is a direct equity profit-sharing model that includes an income distribution benefit based on international revenue generated by our three biotech assets. Impact, humanitarian, and growth equity are the primary investment themes.
Pharma licensing agreement relationships will build momentum and cash reserves to sustain an escalating yield benefit over the next 5-7 years. We project revenue to begin before the end of Yr. 1 and coincide with our Phase III clinical trials.
In tandem with Reg D & Reg S direct equity participations, the opportunity to create a digital asset exchange listing event will be considered in conjunction with achieving our capital objectives.
Contact Us
M. Damian Billy, Managing Partner
To find out more about our strategic partners, future development and growth expansion, and safe, multi-disease adaptation products, we would be happy to arrange a video conference.
The Econophy Group is rebranding as TRISYNTEC.
999 Vanderbilt Beach Rd, Naples, FL 34108, USA
US direct: 239.410.4747 WhatsApp: 1+ 239.410.4747 mdbilly@econophy.com Linkedin <<https://www.linkedin.com/in/m-d-billy-874529b0/<<
Hours
Open today | 09:00 am – 05:00 pm |
Subscribe
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.